ThirtyFiveBio
Founded upon a deep understanding of the biology of GPR35, this group of drug discovery specialists is targeting the causal and unresolved ‘epithelial dysfunction’ for improved patient outcomes, developing small molecule antagonists of this genetically-validated target.
Beyond Cytokines in Colitis
Guided by human genetics, proprietary bioinformatics and pharmacology, ThirtyFiveBio is deploying GPR35 antagonism as a differentiated approach for the precision treatment of digestive system disorders, targeting the causal biology underlying the disease.
Epithelial dysfunction
Novel insights into into signalling and disease for this epithelial target hold the promise of developing disease-modifying treatments in Colitis.
GPR35 inhibition
World-leading portfolio of small molecule GPR35 antagonists, a platform of clinical opportunities in gastrointestinal diseases.
